The expression of a cell death-inducing gene, Bax, was investigated in 52 cases of Hodgkin's disease in parallel with Epstein-Barr virus status and was compared with the immunodetection of other apoptosis-regulating proteins, Mcl-l, Bcl-2, and Bcl-x. Bax immunostaining was found in 92% of the cases, among them 28% with a strong signal in more than 75%0 of the Reed-Sternberg cells. Mcl-l was positive in 8Oy0 of the cases, whereas Bcl-2 and Bcl-x were found in 5390 and 889'0 of the cases, respectively. Of 48 (89%) Baxpositive tumors, 43 were found to express apoptosis-inhibiting proteins such as Mcl-l or Bcl-2. With the exception of EVERAL DISEASES ARE characterized by an accumulation of cells, notably cancers. Cell accumulation may be the consequence of either increased cell production or decreased cell death.' Programmed cell death, or apoptosis, is a cell suicide mechanism characterized by marked blebbing of the plasma membrane, a reduction in cell volume, condensation of the nucleus, and endonucleolytic cleavage of DNA into nucleosomal-length fragmenk2 Recently, several different cell death regulators have been characterized, including negative modulators of apoptosis such as B~l-2,'.~" BcI-x-L,~ and Mcl-l',' and inducers of apoptosis including Bax' and B~1 -x -s .~ Of interest, it has been shown that Bax and Bcl-2 are able to form homodimers and heterodimers,' and it has been speculated that Bax/Bcl-2 and Bax/Bax protein dimerizations may be associated with cell survival and cell death, respe~tively.~"~ It has recently been reported that the t(14; 18)(q32;q21) translocation, which fuses the Bcl-2 gene located on chromosome band 18q21 to the Ig gene located on chromosome band 14q32, can be detected in Hodgkin's disease (HD) by using a polymerase chain reaction technique.I2 Furthermore, we have recently studied the expression of Bcl-2 and Bclx, a Bcl-2-related protein, in Reed-Stemberg (RS) cells of HD by immunohistochemical techniques and showed a high frequency of Bcl-x-positive tumor samples (86%), whereas Bcl-2 immunostaining was found in only 44% of the cases.13 Therefore, these findings suggest that Bcl-x may play a role in HD. It has been shown by using a yeast two-hybrid system that both the Bcl-2 and Bcl-x-L proteins can interact with other Bcl-2 family proteins, including Mcl-l and Bax." Recently, polyclonal antibodies were generated against human Mcl-1 l4 and human baxl5.l6 proteins that do not cross-react with other Bcl-2 family members. Mcl-l reactivity has been recently described in germinal center lymphocytes and in some interfollicular lymphocytes in reactive lymph nodes, in follicular lymphoma cells, and in the RS cells of 2 cases of HD.I4 Bax immunostaining was found in both germinal center and interfollicular lymphocytes in mouse lymph node.I5 These findings prompted us to study the expression of Mcl-1 and Bax in RS cells of 52 lymph nodes from HD patients and to compare the results with Bcl-2 and Bcl-x. Furthermore, the results were correlated with evidence for apoptotic cells as detected by morphology and the in situ 3' OH-DNA end-labeling technique. In addition, Epstein-Barr virus (EBV) has been frequently detected in HD" and EBV latent membrane protein 1 (LMP1) has been shown to be an up-regulator of Bcl-2." Because 100% of the EBV small RNAs (EBER)-positive HD samples were previously found to be Bcl-x-positive,'3 we performed EBV detection in all cases and correlated these findings with regard to expression of apoptosis-regulating proteins of the Bcl-2 family.
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PATIENTS AND METHODS
Patient characteristics and EBV in situ hybridization. We retrospectively analyzed 52 cases of HD for Mcl-l and Bax expression by immunohistochemistry. We have previously reported on Bcl-x and Bcl-2 gene expression in 44 of these cases." The tissues were lymph node biopsy specimens and were processed routinely as previously described.13 Pathological specimens were accessible for EBV in situ hybridization for all patients by using EBER oligonucleotides, as described elsewhere." Statistical analysis was performed by Yates'corrected x ' test and by Fisher's exact test for small samples.
All tests were two-sided. 1712-12) were used as described previo~sly.'~.'~ The working dilutions were 1:SOO and 1:lOOO for Mcl-1 and Bax, respectively. Antibodies were shown by using a streptavidin-biotin complex reagent (StreptABComplexMRP Duet; product no. K692; Dako, Glostrup, Denmark) after prior antigen retrieval using microwave heating.20 Assessment for positivity was as follows:
negative, < l % of tumor cells positive; +, 1% to SO%; ++, 50% Counr ofupprotic cells. Apoptotic cells were identified in histological sections by their pyknotic nuclei and shrunked size. Because of the heterogeneity in the number of tumor cells, apoptotic cells were counted using an arbitary 5-point scale. The results were quoted as follows: 0, no apoptotic cells (50 fields chosen in infiltrating areas without necrosis); 1, 1 apoptotic cell or less for 10 high-power fields (X400); 2, more than 1 cell for 10 fields to 1 cell per field; 3, more than 1 cell per field to 3 cells per field; 4, more than 3 cells per field. The apoptotic cells were characterized by cell shrinkage, with condensed hyperchromatic nucleus with a deeply eosinophilic cytoplasm, and were often surrounded by a clear halo. Few cells morphologically different from apoptotic cells were observed. These cells had a beaded, crescentic nodular chromatin with an eosinophilic cytoplasm.
In situ 3"OH DNA end-labeling method for apoptosis. The ApopTag peroxidase kit (Oncor, Gaithersburg, MD) was applied on paraffin sections according to the manufacturer's recommendations, Briefly, residues of digoxigenin-nucleotide were catalitically added to the DNA by terminal deoxynucleotidyl transferase in 3"OH ends of double-or single-stranded DNA. The labeling product was visualized using diaminobenzidine, which yielded brown granules mainly localized to apoptotic cells. Cells showing necrotic morphologies can in some instances contain stainable concentrations of DNA ends with the ApopTag kit, but they are expected to be more diffuse than apoptotic cells. The evaluation of the numbers of terminal deoxynucleotidyl transferase (TdT)-end-labeled cells was based on the same counting method applied to apoptotic cells. Separated counts in labeling were performed for RS cells, mummy cells, and small lymphocytes. One case of reactive lymph node with hyperplastic germinal centers and one case of Burkitt's lymphoma served as positive controls (both cases showing frequent apoptotic cells). to 75%; +++, >7S%."
RESULTS
The results for HD subtypes, EBV status, and Bax, Mcl-1, Bcl-2, and Bcl-x immunostaining are shown in Table 1 .
The distribution of the cases according to subtype was as follows: 6, lymphocyte predominance (LP); 16, nodular sclerosis (NS); and 30, mixed cellularity (MC). EBER RNAs were detected in 23 of 52 (44%) cases by in situ hybridization with EBER oligonucleotides. Bax immunostaining was detected in the cytoplasm of RS cells in 48 of 52 (92%) cases (Fig 1) . Immunostaining of interfollicular and germinal center lymphocytes served as a positive internal control, as reported p r e v i o u~l y . '~~~~ In 15 cases (28%), more than 75% of RS cells immunostained positive for Bax (Table 1) . In general, the intensity of the staining was similar (slightly lower in a few cases) to that observed in positive control lymphocytes. Bax immunostaining was found to be statistically related to absence of EBV in the tumor cells, as detected by EBER in situ hybridization (two-sided P value [P21 = ,032). Because Bax has been described as having an apoptosispromoting function' in contrast to Bcl-2,' Mcl-and the long isoform of B~l -x ,~ we looked at Mcl-1 immunostaining and extended our previous findings of Bcl-2 and Bcl-x immunostaining to all cases.I3 Mcl-1 was positively stained in the cytoplasm of RS cells in 42 of 52 (80%) cases (Fig 2) . A positive internal control for Mcl-l was the immunostaining of interfollicular and germinal center lymphocytes.'" As reported previously,13 Bcl-2 and Bcl-x were found in 28 of 52 (53%) and 46 of 52 (88%) HD samples, respectively. Dual expression of Bax/Bcl-2 was found in 28 of 47 (59%) cases, whereas all Bax-negative cases were Bcl-2-negative (P2 = ,035). In Bax-positive tumors, 43 of 48 (89%) expressed the apoptosis-inhibiting proteins Mcl-l and/or Bcl-2. Furthermore, Bcl-x immunostaining was found to be expressed in 4 Bax-positive tumors that did not express either Mcl-1 nor Bcl-2, suggesting that Bcl-x may counteract the apoptotic effect of Bax in at least some cases of HD. No relation was found between EBV status and Mcl-1 (P2 = ,155) or Bcl-2 (P2 = .108). whereas Bcl-x and EBV presence were statistically related (P2 = .028), as reported previously.''
The counts of apoptotic cells varied greatly from case to case. All results are detailed in Table 1 .
The results of the in situ 3"OH DNA end labeling technique showed a similar heterogeneity in the number of positive RS cells. In addition to the labeling of the RS cells (Fig  3) , occasional small (apparently non-neoplastic) lymphocytes were also detected with this method. In addition, in cases with significant numbers of positive RS cells, the cytoplasm of the macrophages was also stained. This reactivity was interpreted as a specific labeling of 3'0H-DNA from apoptotic bodies engulfed in the cytoplasm of the macrophages. No correlations were found between Bax staining and presence of apoptotic cells (P2 = .15) or between Bax staining and the presence of RS cells positively labeled with the in situ 3"OH DNA end-labeling technique (P2 = l ) .
DISCUSSION
For the first time, in this report, we described a high incidence of expression of an apoptosis-inducing gene, Bas, in HD. Human Bax, which has ~2 1 % amino acid sequence identity with Bcl-2, is able to form heterodimers with B~1 -2 "~'~~~ and, when overexpressed, is able to counter Bcl-2 activity by promoting programmed cell death? Bax has been reported to be expressed in numerous normal mouse'5 and humanI6 tissues, including in germinal center and interfollicular lymphocytes of nodes. O f interest, Bcl-2 and Bax belong to an expanding family of cell death-regulating proteins, including Bcl-x and Mcl-l.' Therefore, we analyzed both Bax-positive and Baxnegative HD samples for apoptosis-regulating proteins that are known to be able to inhibit programmed cell death, presumably by heterodimerization with Bax." We found that Mcl-l and Bcl-x were fiquently expressed, although Bcl-2 was present in only 53% of cases, which was in agreement with our previous findings.I3 Interestingly, almost all Bax-positive HD tumors For personal use only. on October 3, 2017. by guest www.bloodjournal.org From is not involved in the apoptotic pathway of at least some HD cases. In some HD samples, Bax expression occurred in cases in which only Bclx but not Bcl-2 or Mcl-l was expressed, suggesting that Bclx may prevent Bax-induced apoptosis in the absence of Bcl-2 or Mcl-l in some HD patients. However, we do not know whether the Bcl-x immunoreactivity detected here represents the anti-apoptotic Bcl-x-L or pro-apoptotic Bcl-x-S forms of the protein. In this regard, it may be difficult to show by immunoblot or reverse transcriptase-polymerase chain reaction which isoforms of BcI-x are expressed in HD samples, because, in most cases, the RS cells represent only 1% or less of the tumor cells. Moreover, because Bcl-x-S differs from Bcl-x-L in that an internal region of 63 amino acids is deleted by alternative splicing and this region is well conserved among Bcl-2 family proteins, thus making it difficult to raise specific antibodies, no specific antibodies are yet available that distinguish the various isoforms of the human Bci-x protein. ' HD, particularly of MC subtype, is considered to be an EBV-associated disease in about 50% of the cases." The EBV protein BHRFI, which has 25% sequence homology to bcl-2,' has been shown to suppress apoptosis in Burkitt's lymphoma and other cell Thus, viral homologs of Bcl-2 may also contribute to apoptosis regulation under some circumstances in HD. Moreover, although not examined in this report, other Bcl-2-interacting proteins such as the recently described Bag-1,26 Bad,*' and Nips-l ,2,3 proteins" might be involved in the regulation of apoptosis in HD and need further study. In addition to Bcl-2 family proteins, apoptosis regulation in EBV-associated tumors may also involve nitric oxide production2' and c-myc deregulation.'"
In conclusion, we have shown that an apoptosis-inducing gene, Bax, is frequently expressed in RS cells of HD and that other apoptosis-regulating gene(s) may be expressed in this setting as well, suggesting strongly that apoptosisregulatory proteins may be implicated in HD pathogenesis. The frequent expression of the apoptosis-promoting protein Bax in HD provides a potential explanation for the good chemoresponses generally obtained for patients with this neoplastic disorder.
